X4 Pharmaceuticals Inc [NASDAQ: XFOR] loss -0.57% on the last trading session, reaching $0.37 price per share at the time.
If compared to the average trading volume of 2.21M shares, XFOR reached a trading volume of 4803471 in the most recent trading day, which is why market watchdogs consider the stock to be active.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Here is what top equities market gurus are saying about X4 Pharmaceuticals Inc [XFOR]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for XFOR shares is $2.68 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on XFOR stock is a recommendation set at 1.33. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
B. Riley Securities have made an estimate for X4 Pharmaceuticals Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on December 12, 2023. While these analysts kept the previous recommendation, B. Riley Securities raised their target price to Buy. The new note on the price target was released on August 30, 2023, representing the official price target for X4 Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $3, while Cantor Fitzgerald analysts kept a Overweight rating on XFOR stock.
The Average True Range (ATR) for X4 Pharmaceuticals Inc is set at 0.07, with the Price to Sales ratio for XFOR stock in the period of the last 12 months amounting to 56.04. The Price to Book ratio for the last quarter was 1.04, with the Price to Cash per share for the same quarter was set at 0.79.
Trading performance analysis for XFOR stock
X4 Pharmaceuticals Inc [XFOR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -37.85. With this latest performance, XFOR shares dropped by -25.81% in over the last four-week period, additionally sinking by -58.96% over the last 6 months – not to mention a drop of -53.79% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for XFOR stock in for the last two-week period is set at 37.83, with the RSI for the last a single of trading hit 36.45, and the three-weeks RSI is set at 38.69 for X4 Pharmaceuticals Inc [XFOR]. The present Moving Average for the last 50 days of trading for this stock 0.5680, while it was recorded at 0.3658 for the last single week of trading, and 0.8461 for the last 200 days.
X4 Pharmaceuticals Inc [XFOR]: A deeper dive into fundamental analysis
X4 Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.80 and a Current Ratio set at 4.89.
X4 Pharmaceuticals Inc [XFOR]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, X4 Pharmaceuticals Inc posted -0.1/share EPS, while the average EPS was predicted by analysts to be reported at -0.15/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.05. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for XFOR.
An analysis of Institutional ownership at X4 Pharmaceuticals Inc [XFOR]
There are presently around $67.66%, or 68.45%% of XFOR stock, in the hands of institutional investors. The top three institutional holders of XFOR stocks are: BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC with ownership of 16.92 million shares, which is approximately 8.4582%. NEA MANAGEMENT COMPANY, LLC, holding 14.99 million shares of the stock with an approximate value of $$8.69 million in XFOR stocks shares; and NEA MANAGEMENT COMPANY, LLC, currently with $$6.19 million in XFOR stock with ownership which is approximately 5.3382%.
